AnaptysBio
ANABNasdaqOther · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M | $75.0M |
| Operating income | $47.9M | −$114.9M | −$164.4M | −$115.2M | −$56.8M | −$23.9M |
| Net income | −$13.2M | −$145.2M | −$163.6M | −$128.7M | −$57.8M | −$19.9M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M | $416.6M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M | $396.7M |
| EPS (diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 |
| Shares out. | 30.7M | 26.8M | 27.9M | 27.7M | 27.4M | 27.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 20.4%
- Net margin
- −5.6%
- Return on equity
- −35.6%
- Return on assets
- −3.6%
- Return on capital (ROCE)
- 14.7%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.21
- Revenue growth (YoY)
- 157.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −9.0%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 4 good- Reported a net loss
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2024-11-29A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
- Phase 2Active Not Recruitingreadout ~2026-01A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Sirenia Capital Management LpPassive (13G)May 15, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Morgan StanleyPassive (13G)Feb 11, 2026
- Millennium Management LlcPassive (13G)Jan 16, 2026
- First Light Asset Management, LlcPassive (13G)Nov 14, 2025
- Goldman Sachs Group IncPassive (13G)Nov 12, 2025
- Fmr LlcPassive (13G)Jun 6, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Feb 14, 2025
- Fairmount Funds Management LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.8M | 7.3 | +7.5% |
| Apr 30, 2026 | 4.5M | 5.5 | +8.7% |
| Apr 15, 2026 | 4.1M | 8.0 | -14.7% |
| Mar 31, 2026 | 4.8M | 6.9 | +0.4% |
| Mar 13, 2026 | 4.8M | 7.6 | -10.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 29, 2026
- Amended charter or bylawsMay 21, 2026
- Results of operationsMay 12, 2026
- Director / officer changeMay 11, 2026
- Entered a material agreement · Completed an acquisition or disposition · Director / officer change · Other material eventApr 20, 2026
- Entered a material agreement · Terminated a material agreement · Director / officer change · Regulation FD disclosureMar 27, 2026
- Results of operations · Regulation FD disclosureMar 3, 2026
- Results of operations · Regulation FD disclosureJan 9, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from AnaptysBio (1)
- First Tracks Biotherapeutics, Inc.TRAXcompletedApr 20, 2026details
From the spin-off filings we track. Follow a company to walk its own history.